Rongji Mu

9PUBLICATIONS

18CO-AUTHORS

Pharmaceutical delivery technologiesHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsRadiation therapy

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (9)

Sort by Publication Date:

|Jun 19, 2026

A Bayesian phase I/II platform design with data augmentation accounting for delayed outcomes.

|May 14, 2026

A Bayesian phase I/II platform design with survival efficacy endpoint for dose optimization.

|Aug 19, 2025

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma.

Peng-Peng Xu, Yue Zhu, Zi-Yang Shi

|May 09, 2025

Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study.

Si-Yuan Chen, Peng-Peng Xu, Ru Feng

|Dec 24, 2024

Different Role of PET-CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab-Based Chemotherapy and Chemo-Free Immunotherapy.

Nan Wang, Xin-Yun Huang, Xu-Feng Jiang

|Sep 10, 2024

A Bayesian latent-subgroup platform design for dose optimization.

Rongji Mu, Xiaojiang Zhan, Rui Sammi Tang

Pageof 2

Frequent Collaborators

Weili Zhao

Ying Yuan

Jin Xu

Lei Dong

Xin Wang

Jian-Da Hu

Wei Sang

Fei Li

Zhangsheng Yu

Yue Zhu

Frequent Collaborators

Weili Zhao

Ying Yuan

Jin Xu

Lei Dong